You are here: Industry Insights > Novartis

News List

Heart failure market worth $16 billion by 2026 as Novartis’ drug triggers growth europeanpharmaceuticalreview
July 06, 2017
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow to $16.1 billion by 2026…
Heart failure market worth $16 billion by 2026 as Novartis’ drug triggers growth europeanpharmaceuticalreview
July 06, 2017
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow to $16.1 billion by 2026…
European Commission approves Novartis's Zykadia for ALK-positive NSCLC patients pharmaceutical-technology
July 04, 2017
The European Commission (EC) has given approval for the expansion of use for Swiss healthcare company Novartis's Zykadia (ceritinib) drug for treatment of advanced non-small cell lung cancer (NSCLC) in the EU.
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced NSCLC cphi-online
July 03, 2017
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival compared with SOC chemotherapy with maintenance.
Novartis' Zykadia gains expanded approval in EU for first-line advanced NSCLC firstwordpharma
June 30, 2017
Novartis' Zykadia gains expanded approval in EU for first-line advanced NSCLC
Novartis gains first-line approval for Zykadia in lung cancer pharmafile
June 30, 2017
Novartis gains first-line approval for Zykadia in lung cancer
Novartis drug cuts cardiovascular risk in heart attack survivors pharmatimes
June 23, 2017
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.
Novartis’ eye drug on par with Eylea but with fewer injections pharmatimes
June 23, 2017
Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.
Novartis pulls off surprise success in cardiovascular risk pharmafile
June 23, 2017
Novartis has posted positive news from the Cantos clinical trial study that saw its drug, Canakinumab, pull of a surprise result to reduce the risk of cardiovascular issues. The reason the results were not expected is due to the method of action of the dr
Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance cphi-online
June 23, 2017
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page